Burk M W, Yu S, Ristow S S, McKhann C F
Int J Cancer. 1975 Jan 15;15(1):99-108. doi: 10.1002/ijc.2910150112.
In vitro lymphocyte stimulation by mitomycin-C-blocked tumor cells has been used to demonstrate tumor-specific antigens in syngeneic murine systems and to follow the evolution of tumor immunity with the tumor-bearing state. Mitomycin-blocked tumor cells stimulated syngeneic lymphocytes from normal mice, from those bearing small tumors (less than 1 cm in diameter) and from tumor-immune mice, sensitized by tumor-cell inoculation and subsequent tumor removal, to undergo increased DNA synthesis as measured by the incorporation of tritiated thymidine. However, lymph-node cells from mice bearing tumors over 1 cm in diameter appeared to be maximally stimulated in vivo and incapable of further stimulation by the same tumor cells in vitro. This was reflected by the progressively increasing background levels of nucleic acid synthesis with the length of tumor-bearing and the size of the tumor. Although lymph-node cells from mice with large tumors did not respond to the same tumor cells in vitro, they did have normal responses to PHA. Within 7-14 days of surgical removal of the tumor, specific lymphocyte responsiveness and background activity returned to previous normal levels, but reinoculation with 10-6 tumor cells resulted in progressive tumor growth and loss of specific in vitro responsiveness when the second tumor had reached the critical size of 1 cm in diameter. Brief exposure of tumor-immune lymph-node cells to a soluble antigen extract of the same tumor resulted in a marked increase in DNA synthetic activity compared to that obtained after exposure to a different tumor extract, muscle extract or medium alone underwent stimulation when cultured with mitomycin-blocked tumor cells. However, normally responsive tumor-immune lymph-node cells, after brief exposure to a soluble antigen extract of the same tumor, initially underwent increased DNA synthesis, but were incapable of further stimulation by mitomycin-blocked tumor cells. Tumor antigen, alone or complexed with antibody, was also demonstrated in the sera of mice bearing large tumors and is thought to be responsible for the refractoriness of lymph-node cells from these mice to further stimulation in vitro. These experiments demonstrate that tumor size and the consequent antigen load to which the tumor-bearing animals is subjected have a profound effect on tumor-specific lymphocyte responsiveness.
丝裂霉素C处理的肿瘤细胞在体外对淋巴细胞的刺激作用,已被用于在同基因小鼠系统中证明肿瘤特异性抗原,并跟踪荷瘤状态下肿瘤免疫的演变。丝裂霉素处理的肿瘤细胞能刺激正常小鼠、携带小肿瘤(直径小于1厘米)的小鼠以及通过接种肿瘤细胞并随后切除肿瘤而致敏的肿瘤免疫小鼠的同基因淋巴细胞,使其通过掺入氚标记的胸腺嘧啶来测量DNA合成增加。然而,来自直径超过1厘米肿瘤小鼠的淋巴结细胞在体内似乎受到了最大程度的刺激,并且在体外不能被相同的肿瘤细胞进一步刺激。这表现为随着荷瘤时间的延长和肿瘤大小的增加,核酸合成的背景水平逐渐升高。虽然来自大肿瘤小鼠的淋巴结细胞在体外对相同的肿瘤细胞没有反应,但它们对PHA有正常反应。在手术切除肿瘤后的7 - 14天内,特异性淋巴细胞反应性和背景活性恢复到先前的正常水平,但再次接种10 - 6个肿瘤细胞会导致肿瘤逐渐生长,并且当第二个肿瘤达到直径1厘米的临界大小时,体外特异性反应性丧失。与暴露于不同肿瘤提取物、肌肉提取物或单独培养基相比,将肿瘤免疫淋巴结细胞短暂暴露于同一肿瘤的可溶性抗原提取物后,DNA合成活性显著增加。用丝裂霉素处理的肿瘤细胞培养时,单独培养基未受到刺激。然而,正常反应的肿瘤免疫淋巴结细胞在短暂暴露于同一肿瘤的可溶性抗原提取物后,最初DNA合成增加,但不能被丝裂霉素处理的肿瘤细胞进一步刺激。在患有大肿瘤的小鼠血清中也证明了单独或与抗体复合的肿瘤抗原,并且认为这是这些小鼠的淋巴结细胞在体外难以被进一步刺激的原因。这些实验表明,肿瘤大小以及荷瘤动物所承受的相应抗原负荷对肿瘤特异性淋巴细胞反应性有深远影响。